Michael Scott Wilson

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 11.1

ph-index = 5

Forward Citations = 74(Granted Patents)

Company Filing History:

15 out of 109

Xenon Pharmaceuticals Inc.

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11639351 - Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents (2023-05-02),

2. 11325902 - Benzenesulfonamide compounds and their use as therapeutic agents (2022-05-10),

3. 11174268 - Benzenesulfonamide compouds and their use as therapeutic agents (2021-11-16),

4. 11149002 - Therapeutic compounds and methods of use thereof (2021-10-19),

5. 10981905 - Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents (2021-04-20),

6. 10752623 - Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors (2020-08-25),

7. 10745392 - Benzenesulfonamide compounds and their use as therapeutic agents (2020-08-18),

8. 10526285 - Therapeutic compounds and methods of use thereof (2020-01-07),

9. 10457654 - Therapeutic compounds and methods of use thereof (2019-10-29),

10. 10125098 - Therapeutic compounds and methods of use thereof (2018-11-13),

11. 10005724 - Therapeutic compounds and methods of use thereof (2018-06-26),

12. 9694002 - Substituted benzamides and methods of use thereof (2017-07-04),

13. 9550775 - Substituted triazolopyridines and methods of use thereof (2017-01-24),

14. 9546164 - Substituted benzamides and methods of use thereof (2017-01-17),

15. 8952169 - N-substituted benzamides and methods of use thereof (2015-02-10),

Title: Michael Scott Wilson: Innovator in Therapeutic Agents

Introduction

Michael Scott Wilson is a prominent inventor based in Burnaby, Canada. He has made significant contributions to the field of therapeutic agents, particularly in the development of compounds that target voltage-gated sodium channels. With a total of 15 patents to his name, Wilson's work has the potential to impact the treatment of various neurological conditions.

Latest Patents

Among his latest patents are two notable inventions: "Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents" and "Benzenesulfonamide compounds and their use as therapeutic agents." Both inventions focus on benzenesulfonamide compounds, which can exist as stereoisomers, enantiomers, tautomers, or mixtures thereof. These compounds are designed for the treatment of diseases associated with voltage-gated sodium channels, such as epilepsy and epileptic seizure disorders.

Career Highlights

Throughout his career, Wilson has worked with leading companies in the pharmaceutical industry, including Xenon Pharmaceuticals Inc. and Genentech, Inc. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Wilson has collaborated with notable professionals in his field, including Thilo Focken and Alla Yurevna Zenova. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Michael Scott Wilson is a distinguished inventor whose work in therapeutic agents has the potential to transform the treatment landscape for neurological disorders. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.